These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 1932740

  • 1. Minimal residual disease in patients with chronic myelogenous leukemia undergoing long-term treatment with recombinant interferon alpha-2b alone or in combination with interferon gamma.
    Opalka B, Wandl UB, Becher R, Kloke O, Nagel-Hiemke M, Moritz T, Beer U, Seeber S, Niederle N.
    Blood; 1991 Nov 01; 78(9):2188-93. PubMed ID: 1932740
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Bcr-abl-positive and -negative clonogenic cells in CML patients undergoing long-term interferon treatment.
    Wandl UB, Bützler R, Niederle N, Kloke O, Mengelkoch B, Becher R, Seeber S, Opalka B.
    Leukemia; 1994 May 01; 8(5):776-9. PubMed ID: 7514245
    [Abstract] [Full Text] [Related]

  • 4. Does BCR-ABL genomic rearrangement persist in CML patients in complete remission after interferon alpha therapy?
    Brizard F, Chomel JC, Veinstein A, Rivet J, Giraud C, Kitzis A, Guilhot F, Brizard A.
    Leukemia; 1998 Jul 01; 12(7):1076-80. PubMed ID: 9665193
    [Abstract] [Full Text] [Related]

  • 5. Long-term treatment of chronic myelogenous leukemia with different interferons: results from three studies.
    Niederle N, Kloke O, Wandl UB, Becher R, Moritz T, Opalka B.
    Leuk Lymphoma; 1993 Jan 01; 9(1-2):111-9. PubMed ID: 8477190
    [Abstract] [Full Text] [Related]

  • 6. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
    Paschka P, Müller MC, Merx K, Kreil S, Schoch C, Lahaye T, Weisser A, Petzold A, König H, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A.
    Leukemia; 2003 Sep 01; 17(9):1687-94. PubMed ID: 12970765
    [Abstract] [Full Text] [Related]

  • 7. Detection of minimal residual disease by polymerase chain reaction in Philadelphia chromosome-positive chronic myelogenous leukemia following interferon therapy.
    Lee MS, Kantarjian H, Talpaz M, Freireich EJ, Deisseroth A, Trujillo JM, Stass SA.
    Blood; 1992 Apr 15; 79(8):1920-3. PubMed ID: 1562719
    [Abstract] [Full Text] [Related]

  • 8. Use of quantitative polymerase chain reaction to monitor residual disease in chronic myelogenous leukemia during treatment with interferon.
    Lion T, Gaiger A, Henn T, Hörth E, Haas OA, Geissler K, Gadner H.
    Leukemia; 1995 Aug 15; 9(8):1353-60. PubMed ID: 7643624
    [Abstract] [Full Text] [Related]

  • 9. Use of alpha-2a-interferon to treat cytogenetic relapse of chronic myeloid leukemia after marrow transplantation.
    Higano CS, Chielens D, Raskind W, Bryant E, Flowers ME, Radich J, Clift R, Appelbaum F.
    Blood; 1997 Oct 01; 90(7):2549-54. PubMed ID: 9326220
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Minimal residual disease in interferon-treated chronic myelogenous leukemia: results and pitfalls of analysis based on polymerase chain reaction.
    Dhingra K, Kurzrock R, Kantarjian H, Baine R, Eastman PS, Ku S, Gutterman JU, Talpaz M.
    Leukemia; 1992 Aug 01; 6(8):754-60. PubMed ID: 1640725
    [Abstract] [Full Text] [Related]

  • 12. A retrospective single centre study of the outcome of five different therapy approaches in 48 patients with relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation.
    Elmaagacli AH, Beelen DW, Schaefer UW.
    Bone Marrow Transplant; 1997 Dec 01; 20(12):1045-55. PubMed ID: 9466277
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group.
    Hochhaus A, Reiter A, Saussele S, Reichert A, Emig M, Kaeda J, Schultheis B, Berger U, Shepherd PC, Allan NC, Hehlmann R, Goldman JM, Cross NC.
    Blood; 2000 Jan 01; 95(1):62-6. PubMed ID: 10607685
    [Abstract] [Full Text] [Related]

  • 15. Southern technique and cytogenetics are complementary and must be used together in the evaluation of Ph1, M-BCR positive chronic myeloid leukemia (CML) patients treated with alpha interferon (IFN-alpha).
    Steegmann JL, Requena MJ, Casado LF, Pico M, Peñarrubia MJ, Ferro MT, Resino M, Fernandez-Rañada JM.
    Am J Hematol; 1996 Nov 01; 53(3):169-74. PubMed ID: 8895687
    [Abstract] [Full Text] [Related]

  • 16. Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-alpha.
    Hochhaus A, Lin F, Reiter A, Skladny H, van Rhee F, Shepherd PC, Allan NC, Hehlmann R, Goldman JM, Cross NC.
    Br J Haematol; 1995 Sep 01; 91(1):126-31. PubMed ID: 7577619
    [Abstract] [Full Text] [Related]

  • 17. Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity.
    Kurzrock R, Estrov Z, Kantarjian H, Talpaz M.
    J Clin Oncol; 1998 Apr 01; 16(4):1526-31. PubMed ID: 9552062
    [Abstract] [Full Text] [Related]

  • 18. Complete cytogenetic conversion in chronic myelocytic leukemia patients undergoing interferon alpha therapy: follow-up with reverse polymerase chain reaction.
    Bilhou-Nabera C, Viard F, Marit G, Gharbi MJ, Salzes S, Reiffers J, Broustet A, Bernard P.
    Leukemia; 1992 Jun 01; 6(6):595-8. PubMed ID: 1602797
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.